Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Mohammad Eskandari, Yang Shi, John Liu, Joseph Albanese, Swati Goel, Amit Verma & Yanhua Wang. (2021) The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor. Leukemia & Lymphoma 62:1, pages 167-175.
Read now
Read now
Talha Badar, Aniko Szabo, David Sallman, Rami Komrojki, Jefferey Lancet, Eric Padron, Jinming Song & Mohammad Omar Hussaini. (2020) Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leukemia & Lymphoma 61:6, pages 1418-1427.
Read now
Read now
Felicetto Ferrara & Alessandra Picardi. (2020) Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation?. Expert Review of Hematology 13:2, pages 99-108.
Read now
Read now
Marte Karen Brattås, Håkon Reikvam, Tor Henrik Anderson Tvedt & Øystein Bruserud. (2019) Precision medicine for TP53-mutated acute myeloid leukemia. Expert Review of Precision Medicine and Drug Development 4:5, pages 263-274.
Read now
Read now
Rui Huang, Xiwen Liao & Qiaochuan Li. (2018) Identification of key pathways and genes in TP53 mutation acute myeloid leukemia: evidence from bioinformatics analysis. OncoTargets and Therapy 11, pages 163-173.
Read now
Read now
Elise Aasebø, Sushma Bartaula-Brevik, Maria Hernandez-Valladares & Øystein Bruserud. (2018) Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. Expert Review of Hematology 11:1, pages 13-24.
Read now
Read now
Tracy Murphy & Karen W. L. Yee. (2017) Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy 18:16, pages 1765-1780.
Read now
Read now
Articles from other publishers (38)
Adelaide Kwon & Olga K. Weinberg. (2023) Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes. Clinics in Laboratory Medicine 43:4, pages 657-667.
Crossref
Crossref
Qing Ling, Shihui Mao, Jiajia Pan, Wenwen Wei, Yu Qian, Fenglin Li, Shujuan Huang, Wenle Ye, Xiangjie Lin, Jiansong Huang, Jinghan Wang & Jie Jin. (2023) CPT1B, a metabolic molecule, is also an independent risk factor in CN-AML. Cancer Biomarkers 37:3, pages 133-145.
Crossref
Crossref
Jennifer A. Marks, Xin Wang, Elena M. Fenu, Adam Bagg & Catherine Lai. (2023) TP53 in AML and MDS: The new (old) kid on the block. Blood Reviews 60, pages 101055.
Crossref
Crossref
Naval G. Daver, Shahed Iqbal, Julie Huang, Camille Renard, Joyce Lin, Yang Pan, Mellissa Williamson & Giridharan Ramsingh. (2023)
Clinical characteristics and overall survival among acute myeloid leukemia patients with
TP53
gene mutation or chromosome 17p deletion
. American Journal of Hematology.
Crossref
Crossref
Naval G. Daver, Shahed Iqbal, Camille Renard, Rebecca J. Chan, Ken Hasegawa, Hao Hu, Preston Tse, Jiajun Yan, Michael J. Zoratti, Feng Xie & Giridharan Ramsingh. (2023) Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. Journal of Hematology & Oncology 16:1.
Crossref
Crossref
Guoxiang Qin & Xueling Han. (2023) The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis. Transfusion Medicine and Hemotherapy 50:3, pages 234-244.
Crossref
Crossref
Cong Shi, Shengping Gong, An Wu, Shujun Yang, Duobing Zou, Yi Zhang, Ningning Wu, Chao Ma, Songqiu Shi, Ying Chen, Ying Wu, Xiaojiao Zheng, Zhenya Huang, Jianghua Ding, Guifang Ouyang & Qitian Mu. (2022) Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes. BMC Cancer 22:1.
Crossref
Crossref
Brandon J. Aubrey & Andrew M. Brunner. (2022) SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes. Clinical Lymphoma Myeloma and Leukemia 22:12, pages 869-877.
Crossref
Crossref
Yixuan Guo, Zhaoyun Liu, Lixiang Duan, Hongli Shen, Kai Ding & Rong Fu. (2022) Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation. Investigational New Drugs 40:4, pages 738-746.
Crossref
Crossref
Youshan Zhao, Juan Guo, Sida Zhao, Roujia Wang, Lei Shi, Ying Fang, Zheng Zhang, Luxi Song, Dong Wu & Chunkang Chang. (2022) Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome. Cancers 14:12, pages 2984.
Crossref
Crossref
Minhua Li, Feifei Lan, Chen Li, Ning Li, Xiaojie Chen, Yueyuan Zhong, Yue Yang, Yingqi Shao, Yi Kong, Xinming Li, Danny Wu, Jingyu Zhang, Wenqing Chen, Zesong Li & Xiao Zhu. (2022) Expression and Regulation Network of HDAC3 in Acute Myeloid Leukemia and the Implication for Targeted Therapy Based on Multidataset Data Mining. Computational and Mathematical Methods in Medicine 2022, pages 1-14.
Crossref
Crossref
Shengnan Yuan, Xiaomin Wang, Shuaibing Hou, Tengxiao Guo, Yanjie Lan, Shuang Yang, Fei Zhao, Juan Gao, Yuxia Wang, Yajing Chu, Jun Shi, Tao Cheng & Weiping Yuan. (2021) PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. Leukemia 36:2, pages 370-382.
Crossref
Crossref
Avner Fink, Eric Hung, Indranil Singh & Yinon Ben‐Neriah. (2021) Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet. European Journal of Immunology 52:1, pages 34-43.
Crossref
Crossref
Lingling Shi, Rui Huang & Yongrong Lai. (2021) Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemia. BMC Medical Genomics 14:1.
Crossref
Crossref
Xingjuan Wang, Xi Chen, Hu Dou, Zhenzhen Yang, Junqin Bi, Yi Huang, Guo Fu, Lan Yuan, Ling Lu, Jie Yu & Liming Bao. (2021) Monosomal karyotype as an adverse risk factor for inferior survivals in children with acute myeloid leukemia. Pediatric Hematology Oncology Journal 6:4, pages 158-165.
Crossref
Crossref
Sonja Heibl, Reinhard Stauder & Michael Pfeilstöcker. (2021) Is Myelodysplasia a Consequence of Normal Aging?. Current Oncology Reports 23:12.
Crossref
Crossref
Juanjuan Song, Baojun Shang, Yanru Pei, Mingyue Shi, Xiaona Niu, Liurui Dou, Emmanuel Kwateng Drokow, Fangfang Xu, Yanliang Bai & Kai Sun. (2021) A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia. Leukemia Research 109, pages 106638.
Crossref
Crossref
Beata Balla, Florin Tripon & Claudia Banescu. (2021) From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques. International Journal of Molecular Sciences 22:18, pages 10065.
Crossref
Crossref
Jesus D. Gonzalez-Lugo, Samarpana Chakraborty, Amit Verma & Aditi Shastri. (2021) The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia. Seminars in Hematology 58:1, pages 56-65.
Crossref
Crossref
Jifeng Yu, Yingmei Li, Danfeng Zhang, Dingming Wan & Zhongxing Jiang. (2020) Clinical implications of recurrent gene mutations in acute myeloid leukemia. Experimental Hematology & Oncology 9:1.
Crossref
Crossref
Esha Madan, Maria Leonor Peixoto, Peter Dimitrion, Timothy D. Eubank, Michail Yekelchyk, Sarmistha Talukdar, Paul B. Fisher, Qing-Sheng Mi, Eduardo Moreno & Rajan Gogna. (2020) Cell Competition Boosts Clonal Evolution and Hypoxic Selection in Cancer. Trends in Cell Biology 30:12, pages 967-978.
Crossref
Crossref
Cosimo Cumbo, Giuseppina Tota, Luisa Anelli, Antonella Zagaria, Giorgina Specchia & Francesco Albano. (2020) TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings. International Journal of Molecular Sciences 21:10, pages 3432.
Crossref
Crossref
Stephan Bartels, Muhammad Faisal, Guntram Büsche, Jerome Schlue, Britta Hasemeier, Elisa Schipper, Julia Vogtmann, Lina Westphal, Ulrich Lehmann & Hans Kreipe. (2019) Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. Leukemia 34:5, pages 1364-1372.
Crossref
Crossref
Prajwal Dhakal, Bimatshu Pyakuryal, Prasun Pudasainee, Venkat Rajasurya, Krishna Gundabolu & Vijaya Raj Bhatt. (2020) Treatment Strategies for Therapy-related Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 20:3, pages 147-155.
Crossref
Crossref
Alina-Andreea Zimta, Ciprian Tomuleasa, Iman Sahnoune, George A. Calin & Ioana Berindan-Neagoe. (2019) Long Non-coding RNAs in Myeloid Malignancies. Frontiers in Oncology 9.
Crossref
Crossref
Courtney DiNardo & Curtis Lachowiez. (2019) Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions. Current Hematologic Malignancy Reports 14:5, pages 386-394.
Crossref
Crossref
Jung‐hoon Lee, Alan List & David A. Sallman. (2019) Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. European Journal of Haematology 102:3, pages 203-209.
Crossref
Crossref
Michael Leisch, Bettina Jansko, Nadja Zaborsky, Richard Greil & Lisa Pleyer. (2019) Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. Cancers 11:2, pages 252.
Crossref
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Crossref
Angela Gil-Perez & Guillermo Montalban-Bravo. (2019) Management of myelodysplastic syndromes after failure of response to hypomethylating agents. Therapeutic Advances in Hematology 10, pages 204062071984705.
Crossref
Crossref
John S. Welch. (2018) Patterns of mutations in TP53 mutated AML. Best Practice & Research Clinical Haematology 31:4, pages 379-383.
Crossref
Crossref
Stefan O. Ciurea, Abhishek Chilkulwar, Rima M. Saliba, Julianne Chen, Gabriela Rondon, Keyur P. Patel, Haitham Khogeer, Abdul R. Shah, Brion V. Randolph, Jorge M. Ramos Perez, Uday Popat, Chitra M. Hosing, Qaiser Bashir, Rohtesh Mehta, Gheath Al-Atrash, Jin Im, Issa F. Khouri, Partow Kebriaei & Richard E. Champlin. (2018) Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood 131:26, pages 2989-2992.
Crossref
Crossref
Hatice D. Gur, Sanam Loghavi, Guillermo Garcia-Manero, Mark Routbort, Rashmi Kanagal-Shamanna, Andres Quesada, Haitham Khogeer, Sherry Pierce, L. Jeffrey Medeiros, Hagop Kantarjian & Joseph D. Khoury. (2018) Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. American Journal of Surgical Pathology 42:6, pages 799-806.
Crossref
Crossref
Tatiana Denisenko, Anastasia Pivnyuk & Boris Zhivotovsky. (2018) p53-Autophagy-Metastasis Link. Cancers 10:5, pages 148.
Crossref
Crossref
Andrew KuykendallNicolas DuployezNicolas BoisselJeffrey E. LancetJohn S. Welch. (2018) Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. American Society of Clinical Oncology Educational Book:38, pages 555-573.
Crossref
Crossref
Takuji Yamauchi, Takeshi Masuda, Matthew C. Canver, Michael Seiler, Yuichiro Semba, Mohammad Shboul, Mohammed Al-Raqad, Manami Maeda, Vivien A.C. Schoonenberg, Mitchel A. Cole, Claudio Macias-Trevino, Yuichi Ishikawa, Qiuming Yao, Michitaka Nakano, Fumio Arai, Stuart H. Orkin, Bruno Reversade, Silvia Buonamici, Luca Pinello, Koichi Akashi, Daniel E. Bauer & Takahiro Maeda. (2018) Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. Cancer Cell 33:3, pages 386-400.e5.
Crossref
Crossref
Marie Goulard, Christine Dosquet & Christine Chomienne. (2018) Approche personnalisée des conditionnements prétransplantation de patients porteurs de syndromes myélodysplasiques. médecine/sciences 34:1, pages 9-11.
Crossref
Crossref
Jo?o Agostinho Machado-Neto, Paula de Melo Campos, Patricia Favaro, Mariana Lazarini, Renata Scopim-Ribeiro, Irene Lorand-Metze, Fernando Ferreira Costa, Sara Terezinha Olalla Saad & Fabiola Traina. (2017) SIVA, a target of p53, is downregulated in myelodysplastic syndromes. Applied Cancer Research 37:1.
Crossref
Crossref